|
DK2081929T3
(da)
|
2006-11-08 |
2013-04-15 |
Neurocrine Biosciences Inc |
Substituerede 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11B-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol-forbindelser og fremgangsmåder angående disse
|
|
CA2736409C
(en)
|
2008-09-18 |
2017-07-11 |
Auspex Pharmaceutical, Inc. |
Benzoquinoline inhibitors of vesicular monoamine transporter 2
|
|
CA2801061A1
(en)
|
2010-06-01 |
2011-12-08 |
Auspex Pharmaceuticals, Inc. |
Benzoquinolone inhibitors of vmat2
|
|
WO2012000308A1
(zh)
*
|
2010-06-29 |
2012-01-05 |
中国药科大学 |
丁苯那嗪的拆分方法
|
|
US8351329B2
(en)
*
|
2010-09-14 |
2013-01-08 |
Cisco Technology, Inc. |
Universal load-balancing tunnel encapsulation
|
|
CN102285984B
(zh)
*
|
2010-11-25 |
2012-10-10 |
江苏威凯尔医药科技有限公司 |
(2R,3R,11bR)-二氢丁苯那嗪及相关化合物的制备方法
|
|
WO2012081031A1
(en)
*
|
2010-12-15 |
2012-06-21 |
Enaltec Labs Pvt. Ltd. |
Process for preparing tetrabenazine
|
|
CA2883641C
(en)
|
2012-09-18 |
2021-09-14 |
Auspex Pharmaceuticals, Inc. |
Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
|
|
US9550780B2
(en)
|
2012-09-18 |
2017-01-24 |
Auspex Pharmaceuticals, Inc. |
Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
|
|
WO2014120654A1
(en)
|
2013-01-31 |
2014-08-07 |
Auspex Pharmaceuticals, Inc. |
Benzoquinolone inhibitors of vmat2
|
|
HK1221645A1
(zh)
*
|
2013-09-27 |
2017-06-09 |
Auspex Pharmaceuticals, Inc. |
Vmat2的苯并喹啉抑制剂
|
|
CN105873589B
(zh)
*
|
2013-12-03 |
2019-11-01 |
奥斯拜客斯制药有限公司 |
制造苯并喹啉化合物的方法
|
|
CA2936823A1
(en)
*
|
2014-01-27 |
2015-07-30 |
Auspex Pharmaceuticals, Inc. |
Benzoquinoline inhibitors of vesicular monoamine transporter 2
|
|
CA2938581C
(en)
|
2014-02-07 |
2023-02-28 |
Neurocrine Biosciences, Inc. |
Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof
|
|
WO2015120110A2
(en)
|
2014-02-07 |
2015-08-13 |
Auspex Pharmaceuticals, Inc. |
Novel pharmaceutical formulations
|
|
KR102421235B1
(ko)
|
2014-02-13 |
2022-07-15 |
인사이트 코포레이션 |
Lsd1 저해제로서 사이클로프로필아민
|
|
HUE057839T2
(hu)
*
|
2014-05-06 |
2022-06-28 |
Neurocrine Biosciences Inc |
Valbenazin adagolási rendje hiperkinetikus mozgás-zavarok kezelésére
|
|
KR102586138B1
(ko)
|
2015-02-06 |
2023-10-05 |
뉴로크린 바이오사이언시즈 인코퍼레이티드 |
[9,10-디메톡시-3-(2-메틸프로필)-1H,2H,3H,4H,6H,7H,11bH-피리도-[2,1-a]이소퀴놀린-2-일]메탄올 및 그와 관련된 화합물, 조성물 및 방법
|
|
CN114767672A
(zh)
|
2015-03-06 |
2022-07-22 |
奥斯拜客斯制药有限公司 |
氘代丁苯那嗪或包含氘代丁苯那嗪的组合物
|
|
UA122688C2
(uk)
|
2015-04-03 |
2020-12-28 |
Інсайт Корпорейшн |
Гетероциклічні сполуки як інгібітори lsd1
|
|
WO2016210180A2
(en)
*
|
2015-06-23 |
2016-12-29 |
Neurocrine Biosciences, Inc. |
Vmat2 inhibitors for treating neurological diseases or disorders
|
|
JP7427363B2
(ja)
|
2015-08-12 |
2024-02-05 |
インサイト・ホールディングス・コーポレイション |
Ｌｓｄ１阻害剤の塩
|
|
MX383906B
(es)
|
2015-10-09 |
2025-03-14 |
Teva Pharmaceuticals Int Gmbh |
Combinación de levodopa deuterado con carbidopa y opicapona para el tratamiento del mal de parkinson
|
|
IL284874B2
(en)
*
|
2015-10-30 |
2023-10-01 |
Neurocrine Biosciences Inc |
Valbenazine salts and polymorphs thereof
|
|
LT3394057T
(lt)
*
|
2015-12-23 |
2022-06-27 |
Neurocrine Biosciences, Inc. |
Sintezės būdas, skirtas pagaminti (s)-(2r,3r,11br)-3-izobutil-9,10-dimetoksi-2,3,4,6,7,11b-heksahidro-1h-pirido[2,1-a]izochinolin-2-ilo 2-amino-3-metilbutanoato di(4-metilbenzensulfonatą)
|
|
US10479787B2
(en)
|
2016-04-22 |
2019-11-19 |
Lupin Limited |
Process for preparation of tetrabenazine and deutetrabenazine
|
|
EP3473623B1
(en)
*
|
2016-06-29 |
2020-07-15 |
Crystal Pharmaceutical (Suzhou) Co., Ltd. |
Crystal forms of nbi-98854, preparation method therefor and use thereof
|
|
RU2019110048A
(ru)
*
|
2016-10-06 |
2020-11-06 |
Ассиа Кемикал Индастрис Лтд. |
Твердые формы валбеназина
|
|
TW202345829A
(zh)
|
2016-12-02 |
2023-12-01 |
美商紐羅克里生物科學有限公司 |
戊苯那嗪（valbenazine）於治療精神分裂症或情感性精神分裂症之用途
|
|
WO2018130345A1
(en)
|
2017-01-10 |
2018-07-19 |
Sandoz Ag |
Crystalline valbenazine free base
|
|
KR20230169457A
(ko)
|
2017-01-27 |
2023-12-15 |
뉴로크린 바이오사이언시즈 인코퍼레이티드 |
특정 vmat2 억제제의 투여 방법
|
|
CA3054238A1
(en)
|
2017-02-27 |
2018-08-30 |
Sandoz Ag |
Crystalline forms of valbenazine salts
|
|
WO2018164996A1
(en)
|
2017-03-06 |
2018-09-13 |
Neurocrine Biosciences, Inc. |
Dosing regimen for valbenazine
|
|
US11813232B2
(en)
|
2017-03-15 |
2023-11-14 |
Auspex Pharmaceuticals, Inc. |
Analogs of deutetrabenazine, their preparation and use
|
|
GB201705304D0
(en)
|
2017-04-01 |
2017-05-17 |
Adeptio Pharmaceuticals Ltd |
Pharmaceutical compositions
|
|
GB201705303D0
(en)
|
2017-04-01 |
2017-05-17 |
Adeptio Pharmaceuticals Ltd |
Pharmaceutical compositions
|
|
GB201705306D0
(en)
|
2017-04-01 |
2017-05-17 |
Adeptio Pharmaceuticals Ltd |
Pharmaceutical compositions
|
|
GB201705305D0
(en)
|
2017-04-01 |
2017-05-17 |
Adeptio Pharmaceuticals Ltd |
Pharmaceutical compositions
|
|
RU2768738C2
(ru)
*
|
2017-04-01 |
2022-03-24 |
Адептио Фармасьютикалз Лимитед |
ПРИМЕНЕНИЕ (-)-α-ДИГИДРОТЕТРАБЕНАЗИНА ИЛИ ЕГО КОМБИНАЦИИ С (+)-α-ДИГИДРОТЕТРАБЕНАЗИНОМ В ЛЕЧЕНИИ ГИПЕРКИНЕТИЧЕСКОГО ДВИГАТЕЛЬНОГО РАССТРОЙСТВА, А ТАКЖЕ СООТВЕТСТВУЮЩИЕ СПОСОБЫ
|
|
GB201705302D0
(en)
|
2017-04-01 |
2017-05-17 |
Adeptio Pharmaceuticals Ltd |
Pharmaceutical compositions
|
|
JOP20190239A1
(ar)
|
2017-04-19 |
2019-10-09 |
Neurocrine Biosciences Inc |
مركبات مثبطة لـ vmat2 وتركيبات منها
|
|
US20200179352A1
(en)
|
2017-04-26 |
2020-06-11 |
Neurocrine Biosciences, Inc. |
Use of valbenazine for treating levodopa-induced dyskinesia
|
|
RS66714B1
(sr)
|
2017-09-21 |
2025-05-30 |
Neurocrine Biosciences Inc |
Formulacija visoke doze valbenazina i sastavi, postupci i kompleti povezani sa njim
|
|
MX2020003421A
(es)
*
|
2017-10-10 |
2020-07-20 |
Neurocrine Biosciences Inc |
Metodos para la administracion de ciertos inhibidores del transportador vesicular de monoamina 2 (vmat2).
|
|
KR20250070134A
(ko)
|
2017-10-10 |
2025-05-20 |
뉴로크린 바이오사이언시즈 인코퍼레이티드 |
특정 vmat2 억제제의 투여 방법
|
|
CA3081709A1
(en)
*
|
2017-11-08 |
2019-05-16 |
Yuhua Li |
Esters of dihydrotetrabenazine
|
|
WO2019104141A1
(en)
|
2017-11-22 |
2019-05-31 |
Teva Pharmaceuticals Usa, Inc. |
Solid state form of valbenazine
|
|
EP3733666B1
(en)
|
2017-12-26 |
2022-09-21 |
Crystal Pharmaceutical (Suzhou) Co., Ltd. |
Crystal form of valbenazine di-p-toluenesulfonate, preparation method thereof and use thereof
|
|
CN110092785A
(zh)
*
|
2018-01-31 |
2019-08-06 |
广东东阳光药业有限公司 |
一种丁苯那嗪的动态拆分方法
|
|
GB201808464D0
(en)
|
2018-05-23 |
2018-07-11 |
Adeptio Pharmaceuticals Ltd |
Pharmaceutical compounds for use in treating huntington's disease
|
|
EP3806856A1
(en)
*
|
2018-06-14 |
2021-04-21 |
Neurocrine Biosciences, Inc. |
Vmat2 inhibitor compounds, compositions, and methods relating thereto
|
|
MA53239A
(fr)
|
2018-08-15 |
2022-05-04 |
Neurocrine Biosciences Inc |
Procédés d'administration de certains inhibiteurs de vmat2
|
|
WO2020047198A1
(en)
|
2018-08-31 |
2020-03-05 |
Incyte Corporation |
Salts of an lsd1 inhibitor and processes for preparing the same
|
|
EP3860599B1
(en)
|
2018-10-04 |
2024-05-15 |
Adeptio Pharmaceuticals Limited |
(+)-alpha-dihydrotetrabenazine dosage regimen for treating movement disorders
|
|
CA3065236A1
(en)
|
2018-12-27 |
2020-06-27 |
Apotex Inc. |
Novel crystalline form of valbenazine dibesylate
|
|
WO2020213014A1
(en)
|
2019-04-19 |
2020-10-22 |
Mylan Laboratories Limited |
An improved process for the preparation of valbenazine and its salts
|
|
US10689380B1
(en)
|
2019-07-30 |
2020-06-23 |
Farmhispania S.A. |
Crystalline forms of valbenazine ditosylate
|
|
CN114302883B
(zh)
*
|
2019-08-12 |
2022-09-06 |
山东绿叶制药有限公司 |
Vmat2抑制剂及其制备方法和应用
|
|
US10940141B1
(en)
|
2019-08-23 |
2021-03-09 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain VMAT2 inhibitors
|
|
IL291221B2
(en)
|
2019-09-13 |
2026-05-01 |
Neurocrine Biosciences Inc |
Processes for the synthesis of valbenazine
|
|
CN110698397A
(zh)
*
|
2019-10-28 |
2020-01-17 |
南京红杉生物科技有限公司 |
丁苯那嗪中间体及其合成方法、应用和合成用中间产物
|
|
PE20240822A1
(es)
|
2021-03-22 |
2024-04-18 |
Neurocrine Biosciences Inc |
Inhibidores de vmat2 y metodos de uso
|
|
WO2022232060A1
(en)
|
2021-04-26 |
2022-11-03 |
Neurocrine Biosciences, Inc. |
Processes for the synthesis of valbenazine
|
|
CA3220946A1
(en)
|
2021-06-30 |
2023-01-05 |
Angel S. Angelov |
Valbenazine for use in the add-on treatment of schizophrenia
|
|
US20240342160A1
(en)
|
2021-06-30 |
2024-10-17 |
Neurocrine Biosciences, Inc. |
Valbenazine for use in the treatment of dyskinesia due to cerebral palsy
|
|
AU2023232134A1
(en)
|
2022-03-07 |
2024-10-03 |
Neurocrine Biosciences, Inc. |
Valbenazine, a vmat2 inhibitor, as a free base a tosylate or ditosylate salt, for use in the treatment of chorea associated with huntington's disease
|
|
JP2025531352A
(ja)
|
2022-09-21 |
2025-09-19 |
ニューロクライン バイオサイエンシーズ，インコーポレイテッド |
ヘキサヒドロ－２ｈ－ピリド［２，１－ａ］イソキノリンｖｍａｔ２阻害剤および使用の方法
|
|
WO2025038959A1
(en)
|
2023-08-17 |
2025-02-20 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain vmat2 inhibitors
|
|
WO2025038938A1
(en)
|
2023-08-17 |
2025-02-20 |
Neurocrine Biosciences, Inc. |
Valbenazine for use in the treatment of huntington's chorea
|
|
WO2025096823A1
(en)
|
2023-11-01 |
2025-05-08 |
Neurocrine Biosciences, Inc. |
Improvement, maintenance or reduction of decline of motor function associated with huntington disease using valbenazine
|
|
WO2025188830A1
(en)
|
2024-03-06 |
2025-09-12 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain vmat2 inhibitors
|
|
WO2025199234A1
(en)
|
2024-03-20 |
2025-09-25 |
Neurocrine Biosciences, Inc. |
Vmat2 inhibitors and methods of use
|
|
WO2026050236A1
(en)
|
2024-08-27 |
2026-03-05 |
Neurocrine Biosciences, Inc. |
Muscarinic receptor agonist in combination with a vesicular monoamine transporter 2 inhibitor, for use in the treatment of a neurological or psychiatric disorder
|